Sino Biopharmaceutical Limited has announced that its jointly developed drug, LM-108, a CCR8 monoclonal antibody, has been included in the Breakthrough Therapy Designation (BTD) process by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China. This development, in collaboration with LaNova Medicines Limited, aims to treat CCR8-positive advanced gastric/gastroesophageal junction adenocarcinoma in patients who have not responded to first-line standard therapy. This inclusion in the BTD process marks a significant step forward in the development of next-generation immunotherapy options for tumors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。